Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Status:
Recruiting
Trial end date:
2024-02-07
Target enrollment:
Participant gender:
Summary
This is a phase 2 study that will assess the investigational drug, cabozantinib, in patients
with liver cancer (specifically hepatocellular carcinoma) and who had received a liver
transplant as a part of curative care, but the cancer has come back (recurred). The purpose
of this study is to see how useful cabozantinib is in controlling the disease of these
patients.
Cabozantinib blocks the function of various proteins found on the surface of the body's cells
(called receptor tyrosine kinases) that are important in the development of cancer tumors.
All participants will receive cabozantinib until they are no longer receiving benefit from
the study drug or they experience an intolerable side effect.